NICE 'too quick' to block drugs

NICE too readily blocks access to new drugs and lacks research expertise needed to support value-based pricing, health economists have argued.

A report by the University of York’s Centre for Health Economics (CHE) said NICE underuses the option of backing a drug’s use ‘only in research’.

NICE currently has at least four options when assessing new technologies: reject, approve, approve only in research and approve with research. But NICE rarely recommends approval only in research or with research, the CHE said.

When value-based pricing is introduced, restricted approvals will be important as they broaden options for negotiation alongside cost-effectiveness assessments, the report argued.

In addition, NICE does not currently have the expertise to determine what types of research are needed to address questions about the cost-effectiveness of drugs, the CHE said.

The University of York team argue that valuable information on cost-effectiveness may not be unavailable when a drug is first launched.

Their paper sets out ways in which the benefits of waiting for new research findings can be balanced against the harm caused by delaying access to a new medicine.

The research was commissioned by NICE and funded by the NHS’s National Institute for Health Research and the Medical Research Council.

Professor Carole Longson, director of NICE’s centre for health technology evaluation, said NICE would be considering the findings carefully. ‘We are continually looking at ways we can improve our ap-praisal processes,’ she said

‘We will, of course, need to wait until the Government has finalised its ideas for how VBP will work before we can confirm our own plans, but we feel our current processes are well-placed for the transition to value-based pricing.’

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

First5 GPs and trainees record videos for new general practice recruitment films

First5 GPs and trainees record videos for new general practice recruitment films

A new series of GP recruitment films for Yorkshire and the Humber region feature...

GPs could face CQC inspection at sites delivering COVID-19 vaccine

GPs could face CQC inspection at sites delivering COVID-19 vaccine

GPs could face CQC inspections at designated sites delivering millions of COVID-19...

COVID-19 vaccination could start 7 December as GPs promised 10 days' notice

COVID-19 vaccination could start 7 December as GPs promised 10 days' notice

GP practices chosen to deliver COVID-19 vaccination will not start the campaign before...

GPs face unfair burden from 'layers of regulation', government admits

GPs face unfair burden from 'layers of regulation', government admits

A government report on NHS bureaucracy admits GPs face a 'particularly high' legislative...

GPs should carry out 45% of consultations remotely after pandemic, says Hancock

GPs should carry out 45% of consultations remotely after pandemic, says Hancock

Nearly half of GP consultations should continue to be delivered remotely after the...

Lockdown exit risks magnifying ‘incredible pressure’ on doctors, BMA warns

Lockdown exit risks magnifying ‘incredible pressure’ on doctors, BMA warns

The government’s plan to exit the national lockdown is ‘full of risks’ and could...